{"id":13040,"date":"2024-08-23T06:15:29","date_gmt":"2024-08-23T04:15:29","guid":{"rendered":"https:\/\/valintermed.com\/?p=13040"},"modified":"2024-08-23T06:15:29","modified_gmt":"2024-08-23T04:15:29","slug":"spasticheskaya-paraplegiya-tip-11","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/spastic-paraplegia-tip-11\/","title":{"rendered":"Spastic paraplegia type 11"},"content":{"rendered":"
<\/div>\n

Spastic paraplegia type 11 (SPG11) is a hereditary neurodegenerative disorder belonging to the group of spastic paraplegias, characterized by progressive deterioration of motor function in the lower extremities due to degeneration of the pyramidal nerve tracts. The disease is caused by mutations in the KIF5A gene, which encodes a protein responsible for cellular transport. SPG11 usually manifests itself in adolescence or early adulthood and affects not only motor systems, but also several other systems, including cognitive and emotional aspects. Typical clinical manifestations include spasticity, weakness of the lower extremity muscles, problems with coordination and, in some cases, sensory disorders.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n